Biotechnology company Immutep (ASX:IMM) obtained positive survival data from the Insight-003 first phase trial, evaluating eftilagimod alpha in combination with Keytruda and chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer, according to a Thursday filing with the Australian bourse.
The study results, with a minimum follow-up of 22 months, showed a median overall survival of 32.9 months, a median progression-free survival of 12.7 months, and a 24-month overall survival rate of 81%, the filing said.
Results also show no new safety signals.
Insight-003, led by the Frankfurt Institute of Clinical Cancer Research, is nearing patient enrollment completion, with further data from the trial expected in 2025, according to the filing.
Immutep shares rose past 8% in midday trade Thursday.
Price (AUD): $0.34, Change: $+0.03, Percent Change: +8.06%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。